Bronchiolitis is an acute lower respiratory tract infection that primarily involves terminal and respiratory bronchioles. The disease may extend to the adjacent alveolar ducts and alveolar space[@b1]. Viral infection is the most common cause of bronchiolitis, and respiratory syncytial virus (RSV) is the most common pathogen[@b2][@b3]. *Mycoplasma* is the smallest free-living, self-replicating microorganism. It is highly transmissible and is a frequent cause of respiratory tract infection in children. The symptoms of MP upper respiratory tract infection are usually mild; one-fifth of infected individuals being asymptomatic, but in some cases, MP causes severe conditions such as organizing pneumonia[@b4][@b5][@b6][@b7][@b8][@b9]. Acute MP infection may also exacerbate asthma or cause asthmatic symptoms[@b10][@b11].

Because MP is difficult to isolate in culture, infections are most often confirmed by polymerase chain reaction (PCR) gene amplification or serology. In children with bronchiolitis, detection rates of 75.8% have been reported for RSV and 2.7% for MP[@b12]. In recent years, the incidence of MP-caused bronchiolitis has been rising. A study of 211 cases of bronchiolitis reported an MP-positive rate of 7.1%; and as with RSV, it was frequently detected in moderate or severe cases[@b13]. In another report[@b14], MP was identified in 34.3% of children with bronchiolitis who were between 6 months and 2 years of age, and who comprised 52.2% of the study subjects. The evidence shows that MP has become an important cause of bronchiolitis in infant patients. In the present study, we aimed to determine the prevalence and seasonal distribution of MP bronchiolitis among infant patients in Suzhou, China. Meanwhile, we compared the clinical characteristics of bronchiolitis caused by MP and by RSV.

Results
=======

Patient characteristics
-----------------------

A total of 674 patients with bronchiolitis were studied, including 225 cases in 2010, 205 in 2011, and 244 in 2012. There were 457 (67.8%) male and 217 (32.2%) female patients. 247 (36.6%) were younger than 6 months of age, 234 (34.7%) were 6 months--1 year of age, 193 (28.6%) were 1--2 years of age. The youngest patient was 35 days old, and the oldest patient was 2 years of age.

Pathogens detected
------------------

Pathogens were identified in 586 of 674 specimens (86.9%). RSV was found in 343 cases (50.9%), MP in 116 cases (17.2%), parainfluenza virus (PIV) III in 41 cases (6.1%), human bocavirus (hBoV) in 36 cases (5.3%), human metapneumovirus (hMPV) in 34 cases (5%), influenza virus B (IVB) in nine cases (1.3%), influenza virus A (IVA) in six cases (0.9%), and PIV II in one case (0.1%). Mixed infection was observed in 35 cases, including 16 of MP + hBoV (45.7%), four of hMPV + hBoV (11.4%), four of hBoV + PIV III (11.4%), 3 cases of RSV + IVA (8.6%), three cases of RSV + hBoV (8.6%), three cases of hMPV + RSV (8.6%), and two cases of hMPV + PIV III (5.7%), respectively.

Prevalence of MP and RSV infections in different years and seasons
------------------------------------------------------------------

The annual MP-positive rates were 16.6% (2010), 17.8% (2011), and 17.2% (2012). MP was detected throughout the year with a epidemic peaks observed each year between July and September. The lowest MP-positive rates were January to February and November to December each year. The seasons in the Suzhou area of China were defined as spring (March--May), summer (June--August), autumn (September--November), and winter (December--February). The peaks of MP occurrence thus occurred in the summer and early autumn. The highest rates occurred in September 2010 (44.4%), August 2011 (62.5%), and July 2012 (58.3%), showing a peak that occurred earlier in successive years and higher infection rates in 2011 and 2012 than in 2010. The highest rates of RSV infection were seen to occur between November of one year and March of the following year. The lowest RSV-positive rates were observed each year between June and September. ([Figure 1](#f1){ref-type="fig"}).

Prevalence of MP infection differed with age but not sex
--------------------------------------------------------

Among the 116 cases of MP infection, the youngest patient was 2 months and the oldest was 2 years of age. The median age was 10 months (range: 6--15 months); 22 cases (19%) were less than 6 months of age, 56 (48.3%) were 6 months to 1 year, 38 (32.7%) were 1--2 years of age. The MP positivity rate in patients between 6 months and 1 year of age was significantly higher than that in other age groups (*P* \< 0.01). Sixty cases occurred in males and 56 in females (M:F = 1.07:l). The difference was not statistically significant.

Clinical characteristics of patients infected with MP
-----------------------------------------------------

Various degrees of fever were recorded in 38 cases (32.8%). The median duration of fever was 3.5 ± 1.0 days. Patients had differing severity of cough and wheezing; there were 13 cases (11.2%) of tachypnea or dyspnea, seven (6%) of O~2~ saturation \< 90%, and 98 cases (84.5%) of lung rales and (or) wheezing.

The median white blood cell counts were 7.7 ± 3.5 × 10^9^/l, mean C-reactive protein (CRP) was 8.5 ± 3.8 mg/l; 79 cases (68.1%) had peripheral blood platelet counts \> 400 × 10^9^/l. Thirty patients (25.8%) had elevated alanine aminotransferase (ALT) levels, 41 (35.5%) had elevated creatine kinase MB isoenzyme (CK-MB). The radiological analysis was performed by a radiologist blinded to the pathogens that had been isolated. Abnormal chest X-ray findings were seen in 332 patients (88.3%), including 77 cases (66.4%) of pulmonary interstitial infiltration, 14 (12.1%) of patchy shadows, and 19 (16.4%) of emphysema. Thirty-three cases had vomiting and/or diarrhea. All patients improved or were cured, and were discharged from hospital. The average hospital stay was 7 days (range, 6.3--9.0 days; [Table 1](#t1){ref-type="table"}).

Characteristics of patients with MP or RSV infection
----------------------------------------------------

The average age was 10 months in MP patients and 5.2 months in RSV patients. Low fever was more common in children with RSV than MP infection, and high fever was more common in MP than RSV infection. SaO~2~ \< 90% was more common in children with RSV than MP infection. Thrombocytosis, increased ALT and CK-MB were more common in children with MP infection than those with RSV infection. Pulmonary interstitial infiltration was more common in children infected with MP than those with RSV ([Figure 2](#f2){ref-type="fig"}). Emphysema was more common in children with RSV than those with MP infection ([Figure 3](#f3){ref-type="fig"}). The average hospital stay was longer in children with RSV than in those with MP infection ([Table 2](#t2){ref-type="table"}).

Discussion
==========

In this study, MP was the second most frequently identified bronchiolitis pathogen after RSV, found in 17.2% of the cases. The detection rate of MP was higher than that in previous reports. Liu WK et al.[@b15] reported an MP-positive rate of 11.3% in children with acute respiratory infections in Guangzhou. Pientong et al.[@b16] studied 170 bronchiolitis cases with an MP detection rate of 8.2%. Our data suggest that the proportions of bronchiolitis cases in infants that are caused by MP, and the importance of MP as a bronchiolitis pathogen, are increasing.

We note that a PCR assay may reveal small numbers of organisms that are not the cause of infection. Therefore, a highly sensitive detection method such as non-quantitative PCR may overestimate the clinical importance of M pneumoniae as a pathogen. The results obtained with the method as used here (i.e., qRT-PCR, Ct curves) depended on the amount of target sequence in the starting (clinical) sample, and although there is no agreement on the CCU/ml indicative of infection, a cutoff value was chosen based on the available published data. The reasons we considered these patients were infected rather than colonized by *M. pneumoniae* are as follows. 1) The patients were being treated for a current diagnosis of bronchiolitis. All had ongoing clinical manifestations of lower respiratory tract infection. 2) We used quantitative PCR to detect MP-DNA in patient sputum. 3) The cutoff value for the detected copy number in the MP-PCR assay was set at \>10^5^ CCU/ml for MP infection. A specific threshold for *Mycoplasma* in the respiratory tract that can differentiate colonization from infection has not been established, however a cutoff value for the detected copy number in the MP-PCR assay was set at \>10^5^ CCU/ml. We believe that \<10^2^ CCU/ml is generally considered as indicative of colonization[@b17][@b18]. Skakni et al. used a semiquantitative PCR technique to detect *M. pneumoniae* DNA in clinical samples, and reported high loads (≥10^2^ to ≥10^4^ CCU/ml) of *M. pneumoniae* were found in 8 of 10 patients with acute pneumonia, and low loads (\<10^2^ CCU/ml) in were found in samples from asymptomatic patients[@b17]. Kleemola et al.[@b18] used a commercial Gen-Probe probe test during an epidemic of *M. pneumoniae* infections among army conscripts. Comparison of the probe test results with the *Mycoplasma* culture and serologic results showed that the probe test was sensitive and specific for the rapid diagnosis of acute *M. pneumoniae* infection of the lower respiratory tract when sputum was used. It had good sensitivity (0.95) and specificity (0.85) among patients whose serologic results were consistent with their culture results[@b18].

This is the largest study of MP-caused bronchiolitis in infants and included a series of patients in the Suzhou region over 3 consecutive years. Our data revealed that MP can be detected throughout the year with a peak prevalence between July and September each year, suggesting that the epidemic MP season in the Suzhou region is in summer and early autumn. A previous epidemiological study by Ji et al is consistent with the seasonal pattern presented in this study[@b19]. Our previous study suggested that the MP detection rate was positively correlated with environmental temperature. The higher the temperature, the higher the positivity rate[@b20], which is consistent with other reports[@b21][@b22]. In temperate regions, outbreaks of MP pneumonia commonly occur in summer and early autumn. Respiratory tract infections caused by other pathogens are relatively infrequent at that time. Contrary to this finding, Hadil et al reported a higher prevalence of MP in autumn and only a few cases in winter and spring[@b5]. MP was not detected in summer. Defilippi et al.[@b4] reported the first MP peak in June, and a second peak in December and January. Sidal et al.[@b23] reported the highest prevalence of MP was in winter. But one report including data collected over 11 consecutive years showed that the prevalence of MP had no obvious seasonal differences[@b24]. Overall, the available studies suggest that the epidemiology of MP differs from region to region because of differences in climate.

Previous studies suggested that MP infections occurred mainly in school-age children and adolescents, with the highest prevalence in patients between 5 and 14 years of age[@b25]. MP infection in infants was relatively rare[@b26]. However, this study found that MP bronchiolitis was seen mainly in infants from 6 months to 1 year of age and had a detection rate 23.9% in that group of patients. Evidence that MP infection of infants is increasing comes from reports that 21.6% of patients 2 years of age had throat swabs that were MP-positive[@b4]. The highest prevalence age of MP infection ranges from 6 months to 1 year of age[@b16]. The data obtained in this study are consistent with those reports.

Cough, wheezing, and moderate to high fever of short duration were the main clinical manifestations of MP infection. Elevated ALT, increased myocardial enzymes, thrombocytosis and urticaria can appear in some patients. Chest X-ray examination shows pulmonary interstitial lesions, and both lungs can be involved. Xia et al.[@b27] reported that wheezing and low fever are very common in infants with MP infection. Pulmonary signs and gastrointestinal involvement are common. A recent report suggests that thrombocytosis is very common in children with MP infection and may be related to different stages of inflammation[@b28]. In that series, 8% of children had elevated blood platelet counts when admitted to hospital, and 33% had elevated blood platelets on discharge. Similarly, in this study, 68.1% of children with MP infection had thrombocytosis.

Comparing MP with RSV bronchiolitis, Children with RSV-caused bronchiolitis were younger than those with MP infection. Fever was usually absent or mild in RSV-infected patients, but tachypnea, dyspnea, cyanosis was very common and extrapulmonary involvement was infrequent in those patients. Due to relatively severe symptoms of RSV infection in children, oxygen therapy is usually required, and the hospital stay is relatively long. Overall RSV infection causes more severe symptoms in children than MP does. The study results are consistent with the symptoms described by others[@b16]. We found that extrapulmonary complications, including thrombocytosis, and increased ALT and CK-MB, were more frequent in MP than in RSV infection. Development of autoantibodies is the main cause of extrapulmonary complications in patients with MP infection. Moreover, the chest X-ray had different features in patients with MP and RSV infection. Pulmonary interstitial infiltration was more common in patients with MP infection. Conversely, emphysema was more common in RSV infection. These findings are important in the differential diagnosis of MP and RSV infection.

The major limitation of this study was that serological examinations of MP and other pathogens were absent. Another limitation was the absence of asymptomatic control patients. There was also no standard scoring system to distinguish the different patterns in chest X-ray examinations of patients. We plan to conduct a more extensive study in the near future to address these issues.

Methods
=======

Approvals
---------

All experiments were performed following the relevant guidelines and regulations of Soochow University. The methods were carried out in accordance with the approved guidelines. The study was approved by the Medical Ethics Committee of Soochow University (No. Sdfey201005). The parents of all study participants gave both verbal and written informed consent before study enrollment.

Patients
--------

This retrospective study was conducted from January 2010 to December 2012 in pediatric patients at the Department of Respiratory Disease of the Affiliated Children\'s Hospital, Suzhou University. The diagnosis of bronchiolitis was based on the following criteria[@b29]. (1) The disease occurred within two years of birth. (2) The onset was acute, accompanied by wheezing and dyspnea, and a previous history of upper respiratory tract infection. (3) The patient presented with restlessness, increased respiration and heart rate, nasal symptoms, and cyanosis. (4) Physical examination revealed widespread double lung wheeze during the onset of wheezing, accompanied by fine rales or crepitus. Patients with congenital heart disease, immune deficiency, bronchus, or pulmonary dysplasia were excluded in this study.

Sputum specimen collection
--------------------------

Nasopharyngeal secretions were collected from each study participant within 24 h after admission by a lab technician as previously described. Briefly, an aseptic plastic sputum catheter was inserted into the nostril to a depth of about 7--8 cm until reaching the pharynx. Approximately 2 ml of nasopharyngeal secretions was collected by applying negative pressure. The sample was mixed with 4--8 ml PBS, and centrifuged for 10 minutes at 300--500 rpm. The supernatant was discarded and the pellet was mixed with 4--8 ml PBS and centrifuged for an additional 10 minutes. The pellet was stored at −80°C until testing began.

Sputum MP-DNA detection and evaluation
--------------------------------------

DNA lysate (Shanghai Shenyou biotechnology company, Shanghai, China) was added to the sputum pellet following washing with PBS. The sample was heated to at 95°C for 10 min, centrifuged for 5 min at 12 000 rpm, and then the supernatant was collected. After extracting the DNA from the sputum specimen, MP DNA was detected by fluorescent real-time PCR (BIO-RAD iCycler, USA). The cyclic temperature settings were 93°C, 2 min; 93°C, 45 s; 55°C, 60 s → 10 cycles; 93°C 30 s → 55°C, 45 s → 30 cycles. The fluorescence collection point was set at the 55°C, 45 s. C~t~ value was used to quantify the fluorescence quantitative PCR results. The primer sequences and MP probe are shown in [Table 3](#t3){ref-type="table"}. The probe binding sequence was located between the upstream and downstream primer. The fluorescent reporter dye at the 5′ end of probe was 6-carboxyfluorescein (FAM), and the quencher at the 3′ end of the probe was 6-carboxytetramethylrhodamine (TAMRA). The primers and probe were purchased from Guangzhou Daan Gene Ltd. (Guangzhou, China). An MP-negative sample was defined as having an amplification curve that was not S-shaped or a C~t~ value = 30. Both results indicated that the MP DNA content was below the detection limit. A positive MP sample was defined as having an amplification curve was S-shaped and a C~t~ value \< 30. The DNA content of the sputum was determined by the following criteria. If the sample C \< 5.00 × 10^2^, the DNA content was \<2.5 × 10^3^ gene copies/ml; if 5.00 × 10^2^ ≤ C ≤ 5.00 × 10^8^, the DNA content = 5 × 10^3^ gene copies/ml; and if C \> 5.00 × 10^8^, the DNA content was \>5 × 10^3^ gene copies/ml.

Sputum respiratory virus detection
----------------------------------

Direct immunofluorescence was used to detect syncytial virus infection (RSV), influenza virus A (IVA), influenza virus B (IVB), parainfluenza virus (PIV) I, PIV II, PIV III, and adenovirus (ADV). All assay kits were purchased from Chemicon (USA) and all staining procedures were performed according to the manufacture\'s instructions. Immunostained preparations were viewed with a fluorescence microscope (Leica 020-518.500, Germany).

RNA extraction and real-time PCR to detect the human metapneumovirus (hMPV) gene
--------------------------------------------------------------------------------

RNA was extracted from sputum specimens using Trizol (Invitrogen, USA). cDNA was synthesized by reverse transcription. The cyclic temperature settings were 94°C, 30 s; 55°C, 30 s; 68°C, 30 s; amplified by 45 cycles with the last at 68°C for 7 min. hMPV was assayed by fluorescent real-time PCR (BIO-RAD iCycler). The cyclic temperature settings were 94°C, 30 s; 56°C, 30 s; 72°C, 30 s; amplified, 40 cycles. The primer sequences for hMPV are shown in [Table 3](#t3){ref-type="table"}.

DNA extraction and real-time PCR to detect the human bocavirus (hBoV) gene
--------------------------------------------------------------------------

Sputum DNA was extracted as described above, and hBoV-DNA was detected by real-time fluorescent PCR. The cyclic temperature settings were 94°C, 30 s; 56°C, 30 s; 72°C, 30 s; amplified by 40 cycles. The primer sequences and hBoV probe are shown in [Table 3](#t3){ref-type="table"}.

Statistical analysis
--------------------

All data were analyzed using PASW 20.0 statistical software (IBM, USA). The comparisons among groups were performed using the chi square test. For data that did not meet the conditions of the chi square test, Fisher\'s exact probability test was used. Data with nonnormal distributions, were expressed as medians and quartile ranges (M; P25 P75) and differences were evaluated using the Mann--Whitney U test. *P* \< 0.05 was considered significant.
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![Radiographic characteristics of a patient with *Mycoplasma* bronchiolitis.\
Thickened lung markings accompanied by fuzzy, messy, reticular high-density shadows, with prominence in the hilar region are seen on this chest X-ray.](srep07846-f2){#f2}

![Radiographic characteristics of a patient infected with respiratory syncytial virus.\
The chest X-ray shows increased brightness in both right and left lungs.](srep07846-f3){#f3}

###### Overall characteristics of patients with MP bronchiolitis

  Characteristics                            No. of patients (%)
  ----------------------------------------- ---------------------
  Age                                                  
   \<6 months                                     22 (8.9)
   6 months--1 year                               56 (23.9)
   1--2 years                                     36 (18.6)
  Sex                                                  
   Male                                           60 (51.7)
   Female                                         56 (48.3)
  Fever (°C)                                           
   \<38                                           1 (5.6%)
   38--39                                         5 (13.1%)
   \>39                                          32 (37.2%)
  Symptom                                              
   Cough                                          116 (100)
   Wheezing                                       116 (100)
   Tachypnea                                      13 (11.2)
   Dyspnea                                        13 (11.2)
   Vomiting/diarrhea                              33 (28.4)
  Physical examination                                 
   Lung wheezing rales                            89 (76.7)
   Lung crackles                                   9 (7.8)
  SaO~2~ \< 90%                                     7 (6)
  Lab test                                             
   WBC (×10^9^/l)                                 7.7 ± 3.5
   CRP (mg/L)                                     8.5 ± 3.8
   Blood platelet counts \> 400 × 10^9^/l         79 (68.1)
   ALT↑                                           30 (25.8)
   CK-MB↑                                         41 (35.5)
  Abnormal chest X-ray                                 
   Interstitial infiltration                      77 (66.4)
   Patchy shadows                                 14 (12.1)
   Emphysema                                      19 (16.4)

Data are expressed as number of patients (%) unless otherwise indicated.

WBC, white blood cell counts; CRP, C-reactive protein; ALT, alanine transaminase; CK-MB, creatine kinase-MB.

###### Characteristics of patients with bronchiolitis caused by MP or RSV

  Characteristic                         MP (n = 116), n (%)   RSV (n = 343), n (%)   χ^2^/Z test     *P*
  ------------------------------------- --------------------- ---------------------- ------------- ----------
  Mean age \[months (range)\]             10.0 (6.0--15.0)        5.2 (3.0--9.0)         8.11       \<0.001
   \<6 months                                  22 (19)              208 (60.6)          60.224      \<.0001
   6 months--1 year                           56 (48.3)             84 (24.5)           23.1362     \<.0001
   1--2 years                                 38 (32.7)             51 (14.9)           17.7494     \<.0001
  Sex                                                                                                   
   Male                                       60 (51.7)             257 (74.9            21.84      \<0.001
   Female                                     56 (48.3)             86 (25.1)           21.8426     \<0.0001
  Fever (°C)                                  38 (32.8)             92 (26.8)            1.51        \>0.05
   \<38                                        1 (5.6)              80 (23.3)            30.09      \<0.001
   38--39                                     5 (13.1)               11 (3.2)            0.07        \>0.05
   \>39                                       32 (27.6)              1 (0.3)             96.78      \<0.001
  Symptom                                                                                               
   Cough                                      116 (100)             340 (99.1)         Fisher\'s     0.5751
   Wheezing                                   116 (100)             343 (100)          Fisher\'s       1
   Tachypnea                                  13 (11.2)             98 (28.6)           14.2557      0.0002
   Dyspnea                                    13 (11.2)             86 (25.1)           9.8521       0.0017
   Vomiting/diarrhea                          33 (28.4)             67 (19.8)           4.0429       0.0444
  Physical examination                                                                                  
   Lung wheezing rales                        89 (76.7)             270 (79.6)          0.2021       0.6531
   Lung crackles                               9 (7.8)               32 (9.3)           0.2629       0.6081
  SaO~2~ \< 90%                                7 (6.0)              89 (25.9)            20.78      \<0.001
  Lab tests                                                                                             
   WBC (×10^9^/L) ± [sem]{.smallcaps}         7.7 ± 3.5             7.2 ± 2.9            9.84        \>0.05
   CRP (mg/L) ± [sem]{.smallcaps}             8.5 ± 3.8             7.6 ± 2.3            10.02       \>0.05
   Platelet count \> 400 × 10^9^/l            79 (68.1)             109 (31.7)           15.3        \<0.05
   ALT↑                                       30 (25.8)               31 (9)             21.29      \<0.001
   CK-MB↑                                     41 (35.5)              33 (9.6)            42.42      \<0.001
  Chest X-ray                                                                                           
  Patchy shadow                               14 (12.1)             68 (19.8)            3.55        \>0.05
  Pulmonary emphysema                         19 (16.4)             231 (67.3)           90.79      \<0.001
  Pulmonary interstitial infiltration         77 (66.4)             44 (12.8)           128.06      \<0.001
  Mean hospital stay \[days (range)\]      7.0 (6.3--9.0)         8.0 (7.0--9.0)         5.73       \<0.001
  Medical history                                                                                       
   Premature birth                            18 (15.5)             40 (11.7)            1.17        \>0.05
   Breast feeding                             76 (65.5)             198 (57.7)           2.19        \>0.05
   Eczema                                     38 (32.8)             105 (30.6)           0.19        \>0.05
  Family history of asthma                    14 (12.1)              34 (9.9)            0.43        \>0.05

Data are expressed as number of patients (%) unless otherwise indicated.

MP, *Mycoplasma pneumonia*; RSV, respiratory syncytial virus; WBC, white blood cell counts; CRP, C-reactive protein; ALT, alanine transaminase; CK-MB, creatine kinase-MB.

###### Amplification of *MP*, *hMPV* and *hBoV* genes

  Gene                                       Sequence                             Size (bp)
  ------ --------- ------------------------------------------------------------- -----------
  MP      Forward                5′-CCA ACCAAA CAA CAA CGT TCA-3′                    76
          Reverse                 5′-ACC TTG ACTGGA GGC CGT TA-3′                      
           Probe    5′-FAM-TCA ACT CGA ATA \'ACG GTG ACTTCT TAC CAC TG-3′-TAMRA        
  hMPV    Forward                 5′-AACCGTGTACTAAGTGATGCACTC-3′                     213
          Reverse                  5′-CATTGTTTGACCGGCCCCATAA-3′                        
  hBoV    Forward                 5′-TGACATTCAACTACCAACAACCTG-3′                     92
          Reverse                 5′-CAGATCCTTTTCCTCCTCCAATAC-3′                       
           Probe              5′-FAM-AGCACCACAAAACACCTCAGGGG-3′-TAMRA                  

MP, *Mycoplasma pneumonia*; hMPV, human metapneumovirus; hBoV, human bocavirus; FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine.
